Erectile dysfunction medicines do not cause melanoma, analysis of large studies finds

May 19, 2017
Melanoma in skin biopsy with H&E stain — this case may represent superficial spreading melanoma. Credit: Wikipedia/CC BY-SA 3.0

Use of the erectile dysfunction drug Viagra does not cause the development of melanoma, a deadly form of skin cancer.

This is the main finding of new research led by investigators at NYU Langone Medical Center and its Perlmutter Cancer Center and published online May 19 in the Journal of the National Cancer Institute.

While the researchers found an overall 11 percent increase in the risk of developing melanoma among erection medication users, they found no evidence that medicines cause melanoma. Instead, the study authors attribute the risk to "detection bias," where the group of patients likely to take erection medicines also happens to be more health conscious, more likely to see a doctor, and so more likely to get diagnosed with melanoma than other men of similar age.

"Physicians should still screen for melanoma risk, but they do not need to add the use of Viagra and similar drugs to the list of screening criteria specifically," says urologist Stacy Loeb, MD, MSc, an assistant professor at NYU Langone. "In general, men should continue to be careful about the risk of any kind of skin cancer from excessive sun exposure and use sun protection."

In 2016, the U.S. Food and Drug Administration placed Viagra and other erectile dysfunction drugs collectively known as phosphodiesterase type 5 (PDE5) inhibitors on its watch list of medications with possible safety issues. The FDA action followed a 2014 report in the Journal of the American Medical Association (JAMA) that linked an increased risk of melanoma with Viagra use. Loeb's team, in 2015, published a detailed analysis in JAMA of the medical records of 20,000 men in Sweden that found no evidence that Viagra or similar medicines cause melanoma.

In response to the FDA's action, Loeb and her colleagues analyzed data from five large-scale studies of erectile users and melanoma published between 2014 and 2016, which included a total of 866,049 men, of whom 41,874 were diagnosed with melanoma.

The researchers found an overall increase in melanoma risk among men who used PDE5 inhibitors, but they hypothesized that if a cause and effect exists, higher use of erection medications would be associated with higher risk of developing the disease. Loeb and her colleagues found the opposite: there was an increase in risk among men who had a small amount of exposure to these medications, and men who took larger amounts of erectile dysfunction medications had no significant increase in melanoma risk.

The researchers also reasoned that if erectile dysfunction medications cause melanoma, they would expect to find more aggressive disease among people who take the medications, but that was not the case. They did find an increased risk of early stage melanoma among erection medicine users, but those who took such medications were at a lower risk for than non-users.

"Overall, Viagra and other PDE5 inhibitors are safe medications as long as men are not taking nitrates, which carry a risk of reducing blood pressure," Loeb said. "Physicians and patients should not be concerned about taking these medications on account of worry about ."

Explore further: Viagra does something very important—but it is unlikely to cause melanoma, researchers conclude

Related Stories

Viagra does something very important—but it is unlikely to cause melanoma, researchers conclude

June 23, 2015
A rigorous analysis of more than 20,000 medical records concludes that erectile dysfunction drugs, such as Viagra, are not a cause of melanoma, an often deadly form of skin cancer, despite the higher risk for the disease ...

Taking PDE5 inhibitors for erectile dysfunction unlikely to increase risk of skin cancer

June 14, 2016
Three drugs widely prescribed for erectile dysfunction are unlikely to increase risk of malignant melanoma, according to a study published in the journal PLOS Medicine.

Study examines melanoma incidence, death

December 21, 2016
A new research letter published online by JAMA Dermatology updates information on trends in melanoma incidence and death in the United States since 2009.

Pregnancy does not increase expectant mothers' melanoma risk

April 27, 2017
Expectant mothers need not be concerned that they are more prone to develop melanoma, or will have a worse prognosis if they do get this serious skin cancer, than women who are not pregnant, according to study results published ...

Psoriasis may up risk of melanoma, hematologic cancer

March 28, 2017
(HealthDay)—Patients with psoriasis may have a higher risk of melanoma and hematologic cancers than the general population, according to a study published in the April issue of the Journal of the American Academy of Dermatology.

Erectile dysfunction drugs are safe, possibly beneficial after heart attack

March 9, 2017
Men who filled prescriptions for erectile dysfunction drugs in the years following a heart attack had a substantially lower risk of dying or being hospitalized for heart failure than men who did not use these drugs, according ...

Recommended for you

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

Using artificial intelligence to improve early breast cancer detection

October 17, 2017
Every year 40,000 women die from breast cancer in the U.S. alone. When cancers are found early, they can often be cured. Mammograms are the best test available, but they're still imperfect and often result in false positive ...

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

New assay may boost targeted treatment of non-Hodgkin lymphoma

October 17, 2017
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40% of cases). Recent advancements indicate that both the prognosis and choice of treatment ...

Biology of childhood brain tumor subtypes offers clues to precision treatments

October 17, 2017
Researchers investigating pediatric low-grade gliomas (PLGG), the most common type of brain tumor in children, have discovered key biological differences in how mutated genes combine with other genes to drive this childhood ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.